WHO: Indian strain of COVID-19 resistant to antibodies
Mutations of the Indian strain of COVID-19 indicate its high infectivity and resistance to antibodies in both those who have been ill and vaccinated, the World Health Organization reported.
New varieties of the virus have been discovered in India, including B.1.617. It is a variant with mutations E484Q and L452R that was first identified in India from samples collected on December 1, 2020.
According to preliminary research results, the L452R mutation may interfere with the effectiveness of certain monoclonal antibody treatments. E484Q can neutralize antibodies. Thus, the antibodies that have appeared in a person who has recovered from COVID-19 will not help in the fight against Indian mutations.
Moreover, the new strain is also thought to be highly virulent, which means it is more likely to infect and cause disease.
WHO experts have not yet figured out what influenced the virus mutations in India. One of the factors could be the holding of mass events that increased its spread, as well as the mitigation of antiquated measures in the country.




















Business and mining leader Mark Cutifani to deliver keynote speech at the 3rd Mining Armenia Forum
New AI-Powered Wildlife Monitoring Camera Installed in Paruyr Sevak with the Support of Ucom
35 Years of Trust: IDBank Celebrates with Its Customers
IDBank to Showcase Environmental and Innovative Initiatives at COP17
Ucom Supported Yerevan Conservation Symposium 2026 as Strategic Partner
Unibank Receives B++ Sustainability Alignment Rating from Agents for Impact GmbH
Idram and IDBank Participated in the Opening of My Forest Armenia’s Pavilion at COP17